OBJECTIVE：To compare th e efficacy ，safety and economics of recombinant human follicle stimulating hormone （rFSH）and urin follicle stimulating hormone （uFSH）in the ovulation induction therapy for in vitro fertilization/intracytoplasmic sperm injection-embryo transfer ，and to provide evidence-based evidence for rational use of rFSH in the clinic. METHODS ： Retrieved from PubMed ，Embase，the Cochrane Library ，CNKI，VIP，Wanfang database as well as professional health technology assessment（HTA）database，HTA，systematic review/Meta-analysis and economic studies were collected to compare the effects of rFSH versus urine FSH （uFSH）in ovulation induction for in vitro fertilization/intracytoplasmic sperm injectionembryo transfer （IVF/ICSI-ET）. After literature screening ，data extiaction and quality evaluation ，the conclusions of the included studies were summarized by using qualitative description. RESULTS ：A total of 7 literatures were included ，involving 2 systematic reviews/ Meta-analysis and 5 economic evaluations ，and no HTA report was retrieved. All the studies were reported from abroad. Systematic evaluation/Meta-analysis showed that the number of oocytes obtained in the rFSH group was higher than that in the uFSH group. There was no statistical significance in persistent pregnancy rate ，clinical pregnancy rate ，live birth rate ，abortion rate and the incidence of ovarian hyperstimulation syndrome （OHSS）between 2 groups（P＞0.05）. Economic research showed that rFSH may have cost-effective advantage. CONCLUSIONS ：Current available evidence support that rFSH has simialr efficacy and safety for ovulation induction of IVF/ICSI-ET ，and shows cost-effec- tiveness advantage.